Cases & Investigations

In re Solodyn (Minocycline Hydrochloride) Antitrust Litigation

PRACTICE AREAS: Antitrust
PRODUCT: Brand and generic Solodyn (extended-release minocycline hydrochloride tablets)
CASE STATUS: Settled
SETTLEMENT AMOUNT: $76,846,250

Berger Montague served as co-lead counsel representing a class of direct purchasers of brand and generic Solodyn (extended-release minocycline hydrochloride tablets) alleging that Medicis Pharmaceutical Corp. entered into agreements with each of Impax Laboratories, Inc., Sandoz Inc. and Lupin Limited/Lupin Pharmaceuticals, Inc. not to compete in the market for extended-release minocycline hydrochloride tablets, i.e., Solodyn and its generic equivalents, in violation of the Sherman Act, resulting in the class paying overcharge damages.

After more than four years of litigation and on the eve of trial, the direct purchaser class settled with the last remaining defendant, Impax Laboratories, Inc. In total, the Class received more than $76 million in settlements. Each of the settlements has been preliminarily approved, and the last two settlements received final approval on July 18, 2018.

LEAD ATTORNEYS: David F. Sorensen, Andrew C. Curley, Caitlin G. Costlett, Y. Michael Twersky

Lead Attorneys

David Sorensen Headshot

David F. Sorensen

Managing Shareholder
Andrew Curley Headshot

Andrew C. Curley

Shareholder
Caitlin Coslett Headshot

Caitlin G. Coslett

Shareholder

Request A Free Consultation

  • This field is for validation purposes and should be left unchanged.